Ongoing Clinical Trials for Venous Thrombosis Limb
Currently, there is 1 ongoing clinical trial investigating new treatments for patients with venous thrombosis limb. This trial is exploring whether a medication commonly used for cholesterol management might help prevent recurrent blood clots in the veins. The study is being conducted in France and Norway and focuses on patients who have experienced deep vein thrombosis or pulmonary embolism.
Clinical trial locations
- France
- Norway
Study on Rosuvastatin for Reducing Blood Clots in Patients with Deep Vein Thrombosis or Pulmonary Embolism
This trial is investigating whether Rosuvastatin Calcium, a medication traditionally used to lower cholesterol, can help reduce the risk of recurrent blood clots in patients who have already experienced venous thrombosis. The study will continue until the end of 2027 and is being conducted in France and Norway.
Main inclusion criteria: Participants must be adults, either male or female, who have recently been diagnosed with symptomatic deep vein thrombosis in the upper leg or pulmonary embolism. The diagnosis must have been confirmed within the last 30 days. Deep vein thrombosis must be located in the proximal leg veins, above a specific point called the trifurcation of the popliteal vein. If pulmonary embolism is present, the blockage must be segmental or larger in size.
Main exclusion criteria: The trial excludes patients who are pregnant or breastfeeding. Individuals with severe allergic reactions to Rosuvastatin cannot participate. Those currently taking medications that might interfere with the study drug, or who have severe liver or kidney disease, are not eligible. Patients with recent significant bleeding problems, recent major surgery, or uncontrolled high blood pressure cannot join. The study also excludes individuals with certain heart rhythm problems, a history of alcohol or drug abuse, or those unable to follow study procedures and attend scheduled visits.
Focus and goal: The primary aim is to determine whether taking Rosuvastatin Calcium can lower the rate of major blood clot events in patients who have already experienced a clot. Participants will be randomly assigned to receive either the active medication (20 mg tablets taken orally) or a placebo. Throughout the study, researchers will monitor participants for any recurrence of major blood clots in the legs or lungs. The trial will also assess other health outcomes, including the development of post-thrombotic syndrome, which can occur after a blood clot, as well as other vascular events such as heart attacks or strokes.
Investigational drug: Rosuvastatin is a type of statin medication that works by inhibiting an enzyme called HMG-CoA reductase, which plays a crucial role in cholesterol production in the liver. While statins are commonly prescribed to lower cholesterol levels, this trial is exploring whether Rosuvastatin might also help prevent recurrent blood clots by potentially reducing inflammation and stabilizing blood vessel walls.
Summary
Currently, only one clinical trial is actively recruiting patients with venous thrombosis limb. This study represents an innovative approach to preventing recurrent blood clots by testing a medication outside its traditional use for cholesterol management. The trial is being conducted in two European countries, France and Norway, reflecting international collaboration in researching better prevention strategies for patients who have experienced venous blood clots. The focus on Rosuvastatin is particularly interesting as it explores whether the anti-inflammatory and vessel-stabilizing properties of statins might offer protection beyond their well-known cholesterol-lowering effects. Patients interested in participating should discuss eligibility with their healthcare providers, keeping in mind the specific inclusion and exclusion criteria outlined in the study.